{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:04:09Z","timestamp":1789398249483,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014857","name":"National Natural Science Foundation of China-Guangdong Joint Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The Janus kinases (JAKs) are intracellular tyrosine kinases involved in a broad variety of inflammatory cascades participating in the pathogenesis of systemic lupus erythematosus (SLE). Diffuse non-scarring alopecia is one of the most frequent cutaneous manifestations in SLE, resulting in devastating psychosocial consequences. Although recent studies have shown promising outcomes of the JAK inhibitors in SLE treatment, the efficacy of tofacitinib in diffuse non-scarring alopecia due to SLE has never been reported. Here we present a 29-year-old SLE patient with a 10-year history of refractory severe diffuse non-scarring alopecia who experienced dramatic hair regrowth with tofacitinib. Furthermore, we have made a systematic review regarding the potential effectiveness of tofacitinib in systemic and cutaneous lupus erythematosus. To the best of our knowledge, this is the first case study depicting an SLE patient with refractory alopecia who experienced impressive hair regrowth with the JAK1\/3 inhibitor tofacitinib therapy, which contributes to expanding the field of possible uses of tofacitinib in SLE patients with difficult-to-treat cutaneous involvement, including severe alopecia.<\/jats:p>","DOI":"10.3389\/fimmu.2021.654376","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T20:17:37Z","timestamp":1618431457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib"],"prefix":"10.3389","volume":"12","author":[{"given":"Yu-Lan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Xiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ping","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Zhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0363-8","article-title":"Hair and scalp changes in cutaneous and systemic lupus erythematosus","volume":"19","author":"Udompanich","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.053","article-title":"Nonscarring alopecia in systemic lupus erythematosus: a cross-sectional study with trichoscopic, histopathologic, and immunopathologic analyses","volume":"81","author":"Chanprapaph","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction","volume":"69","author":"Furumoto","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","volume":"78","author":"You","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","article-title":"The Jakinibs in systemic lupus erythematosus: progress and prospects","volume":"28","author":"Mok","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311409963","article-title":"Possible role of the JAK\/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus","volume":"20","author":"Kawasaki","year":"2011","journal-title":"Lupus"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102424","article-title":"JAK\/STAT signaling controls the fate of CD8+CD103+ tissue-resident memory T cell in lupus nephritis","volume":"109","author":"Zhou","year":"2020","journal-title":"J Autoimmunity"},{"key":"B13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12865-017-0225-9","article-title":"JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation","volume":"18","author":"Ikeda","year":"2017","journal-title":"BMC Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13075-016-1034-x","article-title":"JAK3-STAT pathway blocking benefits in experimental lupus nephritis","volume":"18","author":"Ripoll","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209841","article-title":"Familial chilblain lupus due to a gain-of-function mutation in STING","volume":"76","author":"Konig","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/14397595.2015.1069473","article-title":"Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis","volume":"26","author":"Yamamoto","year":"2015","journal-title":"Modern Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez442","article-title":"Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus","volume":"10","author":"Fornaro","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216571","article-title":"Efficacy of JAK 1\/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus","volume":"79","author":"Maeshima","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646872","article-title":"Clinical relevance of circulating anti-ENA and anti-dsDNA secreting cells from SLE patients and their dependence on STAT-3 activation","volume":"47","author":"de la Varga Mart\u00ednez","year":"2017","journal-title":"Eur J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus","volume":"136","author":"Wenzel","year":"2016","journal-title":"J Invest Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.654376\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T20:17:41Z","timestamp":1618431461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.654376\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2021.654376"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.654376","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"article-number":"654376"}}